NCT00052637

Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer

An Open, Comparative, Within Patient, Controlled Phase III, Multicenter Study Of HEXVIX Fluorescence Cystoscopy And White Light Cystoscopy In the Detection Of Carcinoma In Situ In Patients With Bladder Cancer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: Photocure · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Diagnostic procedures such as cystoscopy may improve the ability to detect cancer and to determine the extent of disease. PURPOSE: Diagnostic trial to compare the effectiveness of cystoscopy using hexyl 5-aminolevulinate and two light sources in detecting carcinoma in situ in patients who have bladder cancer.

Detailed description

OBJECTIVES: * Compare blue light fluorescent cystoscopy with reconstituted hexyl 5-aminolevulinate (Hexvix®) vs white light cystoscopy for the detection of carcinoma in situ (CIS) in patients with bladder cancer. * Compare the positive and false detection rates of histologically confirmed non-CIS lesions and dysplasia by these modalities in these patients. * Compare the false detection rate of histologically confirmed CIS lesions by these modalities in these patients. * Compare the number of tumor lesions and dysplasia detected by these modalities in these patients. * Compare management of patients after evaluation with these modalities. * Determine the safety of reconstituted hexyl 5-aminolevulinate (Hexvix®) in these patients. OUTLINE: This is an open-label, multicenter study. Patients undergo bladder catheterization and instillation of reconstituted hexyl 5-aminolevulinate (Hexvix®). After 60 minutes the bladder is evacuated, and the patient undergoes cystoscopic examination of the bladder by white light and then blue light fluorescence. Biopsies are taken of all suspicious areas seen under white and/or blue light modalities, and one normal-appearing area seen under both light modalities, and papillary lesions are resected. Patients are followed at 7 days after procedure. PROJECTED ACCRUAL: A total of 420 patients will be accrued for this study within 1 year.

Conditions

• Bladder Cancer

Interventions

Type	Name	Description
DRUG	hexaminolevulinate
PROCEDURE	biopsy
PROCEDURE	cystoscopy

Timeline

• Start date: 2001-09-01
• Primary completion: 2002-05-01
• First posted: 2003-01-27
• Last updated: 2013-10-23

Locations

1 site across 1 country: United States